Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 1/2 1

Status

Completed 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 81Precursor Cell Lymphoblastic Leukemia-Lymphoma 68Myelodysplastic Syndromes 65Lymphoma, Non-Hodgkin 51Leukemia, Lymphocytic, Chronic, B-Cell 51Hodgkin Disease 47Leukemia 44Leukemia, Myelogenous, Chronic, BCR-ABL Positive 41Multiple Myeloma 40Lymphoma, Mantle-Cell 37Lymphoma, Follicular 36Myeloproliferative Disorders 34Lymphoma 34Lymphoma, B-Cell, Marginal Zone 33Burkitt Lymphoma 32Lymphoma, Large B-Cell, Diffuse 29Leukemia, Myelomonocytic, Chronic 29Hematologic Neoplasms 25Congenital Abnormalities 24Lymphoma, Large-Cell, Immunoblastic 21Leukemia, Myeloid, Accelerated Phase 21Leukemia, Biphenotypic, Acute 20Primary Myelofibrosis 19Leukemia, Myeloid, Chronic-Phase 19Anemia, Refractory, with Excess of Blasts 19Waldenstrom Macroglobulinemia 18Blast Crisis 17Dendritic Cell Sarcoma, Interdigitating 16Lymphoma, Large-Cell, Anaplastic 15Leukemia, Prolymphocytic 15

Interventions

Cyclophosphamide 34Etoposide 25Doxorubicin 20Carboplatin 20Vincristine 19Isotretinoin 19Topotecan 17Temozolomide 17Irinotecan 16Filgrastim 16Melphalan 15Cisplatin 15sargramostim 14Radiotherapy 14Granulocyte-Macrophage Colony-Stimulating Factor 133-Iodobenzylguanidine 12dinutuximab 11Peripheral Blood Stem Cell Transplantation 11naxitamab 9Thiotepa 9Magnetic Resonance Spectroscopy 9humanized 3F8 anti-GD2 monoclonal antibody 7Granulocyte Colony-Stimulating Factor 7Busulfan 7X-Rays 6Specimen Handling 6Phantoms, Imaging 6Ifosfamide 6Antilymphocyte Serum 6fludarabine phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Neuroblastoma × Whole-Body Irradiation × Clear all
NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT00793845 2018-09-18

Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma

Samsung Medical Center

Phase 2 Completed
40 enrolled
CNS

Neuroblastoma

NCT00960739 2016-08-08

MIITOP

Centre Oscar Lambret

Phase 2 Completed
30 enrolled
CNS

Neuroblastoma

NCT00389766 2013-07-10

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡